News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

5

May

2026

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Read More
27

April

2026

Clearmind Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Read More
20

April

2026

Clearmind Welcomes President Trump’s Executive Order as Historic Catalyst for Psychedelic Innovation & Veteran Mental Health Care
Read More
20

April

2026

Clearmind Announced Positive Top-Line Safety Results: CMND-100 Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Read More
15

April

2026

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing CMND-100 Clinical Trial
Read More
14

April

2026

Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Read More
30

March

2026

Clearmind Announces Successful Completion of Treatment for 18 Participants in its Ongoing Phase I/IIa Clinical Trial
Read More
27

March

2026

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Read More
19

March

2026

Clearmind Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical...
Read More
17

March

2026

Clearmind Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Therapies
Read More
13

March

2026

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Read More
11

March

2026

Clearmind Advances Recruitment for CMND-100 Trial's 3rd Cohort at Yale, Johns Hopkins & Tel Aviv Sites Following Positive Results
Read More
10

March

2026

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Read More
4

March

2026

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Read More
9

February

2026

Clearmind Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Clinical Trial
Read More